to the cost of hematology testing, which may make cost-per-test higher than desirable for laboratories with low testing volumes or that serve populations where the ability to recoup costs from clients is limited (eg, impoverished clientele, shelter medicine, wildlife medicine).
Ethylenediaminetetraacetic acid (EDTA)-anticoagulated whole blood samples are inherently labile, deteriorating within hours to days, depending on storage temperature. Storage of canine EDTA whole blood samples for 24 and 48 hours at both 4°C and 24°C is known to cause statistically significant changes in routine CBC measurands, particularly increased HCT, MCV, and MPV, and decreased MCHC. 2, 3 Inherent sample instability (ie, storage artifact) can be deliberately exploited for purposes of analytical error detection (ie, QC) in a process known as repeat patient testing (RPT). The basic principle of RPT is that sample deterioration under prescribed conditions (ie, within a fixed period of time, under specified storage conditions) causes an expected degree of variation in results between a baseline and repeat measurement of the same specimen; variation under the specified conditions exceeding this expected threshold indicates a problem with the test system. 4 It is important that specimens chosen for repeat patient testing-based quality control (RPT-QC) are handled in a similar manner, or excess variability will be introduced (potentially causing "false positives"). 4 QC using RPT is suggested by Westgard (as part of an individualized QC plan) as an alternative for routine statistical QC using commercial QCM and as an additional component for a comprehensive quality plan. 5, 6 In RPT-QC, as in statistical QC using commercial QCM, control data generated during routine daily QC are interpreted according to predetermined, customized control limits calculated from a pilot set of control data and a chosen control rule.
Repeat patient testing-based quality control begins with generating a set of pilot data used to determine control limits; control limits will be used to determine whether future, daily RPT-QC results are acceptable ("in-control") or unacceptable ("out-of-control"). Once control limits are established, the procedure of daily RPT-QC is simple: A patient sample is measured on the day of accession (when the specimen is fresh) and again within an appropriate time interval (ie, within a period of known sample stability, following specified storage conditions). 4 Mathematical differences between the original and repeat results are calculated; these differences are evaluated (ie, compared to the control limits) by plotting on a control chart. RPT-QC data interpretation is analogous to statistical QC using commercial QCM-data points falling outside the control limits indicate greater-than-expected variability in the data and a potential problem with the test system. Using patient samples having relatively normal (mid-range) measurand concentrations/activities is recommended, as these are likely to reflect a typical caseload and avoid extremes where the expected variability may be different or undefined. 4 Exactly how to establish control limits (ie, select a control rule)
for RPT-QC per se is not well documented. A basic principle of control rule selection in statistical QC is that optimal rule choice varies, depending on whether the focus is on detecting unacceptable random error (imprecision) or unacceptable systematic error (bias). For many laboratories, selected rules emphasize detection of unacceptable imprecision, which over time usually also provides adequate control of bias. 7, 8 To begin RPT-QC and determine RPT control limits, Westgard recommends gathering RPT data for at least 20 days and then graphically estimating control limits that contain approximately 95% of the resulting data. 4 Performance of control rules and control limits for detecting analytical error (ie, sensitivity and specificity of the chosen rule and resulting limits for "diagnosing" analytical error) depends upon how many control measurements are made during a single QC event ("n") and the inherent stability of the test system being monitored (its imprecision and bias, or its total analytical error). The probability of error detection (Ped, high when diagnostic sensitivity of the control rule is high) and the probability of false rejection (Pfr, low when diagnostic specificity of the control rule is high) of commonly used control rules can be predicted using established statistical powerfunction curves.
9,10
The question arose whether RPT-QC could be used instead of, or in addition to, commercially available QCM in veterinary clinics or reference laboratories performing hematology testing. The objective of this study was to investigate whether RPT-QC for automated hematology testing of canine specimens could control similar total allowable error (TE a ) compared with the available commercial QCM, with a similar level of Ped and Pfr. The focus was on the 1-3s control rule, since this rule has a low Pfr (0%) and should intuitively be easy to use. Secondary goals were to create tools (eg, instructions, worksheet) that could facilitate implementation of RPT-QC. 
| MATERIALS AND METHODS

| Establishing RPT control limits
Canine EDTA whole blood specimens that arrived as part of the rou- or very close to RIs was chosen per day for inclusion in the study.
Specimens were measured using each instrument at the time of accession and again the following day (approximately 24 hours later).
All Advia 120 measurements were performed by a trained, licensed medical technologist (ie, the technologist on hematology duty that day) according to the manufacturer's instructions and laboratory standard operating procedures. All specimens were checked for appropriate tube-filling and lack of clots prior to analysis. All scil Vet ABC measurements were performed either by one of the authors (B.F.) or by a trained, experienced laboratory assistant according to the manufacturer's instructions. At the conclusion of the workday, all blood specimens were refrigerated overnight at 4°C and were rewarmed and thoroughly mixed prior to repeat measurement the following day.
Data for each measurand and instrument were entered into a spreadsheet (Microsoft Excel, Microsoft Corporation, Redmond, WA, USA). This resulted in a total of n = 12 datasets (6 measurands, each measured using 2 instruments) for evaluation and control limit determination. The following were calculated for each measurand: difference for each data pair, average for each data pair, mean of all data pair averages, standard deviation of the duplicates (SD dup ), and coefficient of variation (CV). In this context, "duplicates" refers to the paired measurements of each RPT specimen. Formulae used were:
where n = the total number of observations (ie, total number of differences).
Given that the focus was on investigating RPT-QC data use with a 1-3s control rule, control limits for each measurand were calculated as 0 AE 3SD dup .
Difference data for each measurand were graphed using the "scatter plot" feature of the "correlation" statistical function in MedCalc software (MedCalc Version 17.2; MedCalc, Ostend, Belgium).
Proposed control limits (0 AE 3SD dup ) were compared numerically and graphically to the full difference dataset used to calculate each control limit. Any differences falling outside the control limits were designated as "extraneous values." For each measurand, if the control limits encompassed all differences, or if extraneous values that were clearly numerically and graphically removed from the remaining differences occurred, then consideration was given to eliminating the 1 or 2 most extraneous values from the dataset on the basis that the control limits could be too wide (too permissive). For all measurands where extraneous values were omitted, the mean, SD dup , CV, and control limits were recalculated. The authors decided final control limits for all measurands by a consensus review.
| Validating RPT control limits
In phase 2 of the study (validation), additional RPT data were collected in the spring of 2016 to assess appropriateness of the chosen control limits. Specimen type, source, identification, handling, and measurement methods were identical to that described above.
Differences between original and repeat results for each measurand and data pair were calculated as described above. Differences were compared to the RPT control limits for that measurand established during phase 1. Also compared were the numerical ranges encompassed by the differences and that encompassed by the control limits from phase 1. Validation criteria were:
• A numerical range encompassed by the differences should be similar (but not necessarily equal) to that encompassed by the control limits.
• 1-3 differences outside the control limits were considered acceptable (validated).
• 4 or more differences outside the control limits suggested limits were too narrow (restrictive).
• 0 differences outside the control limits, or differences encompassing a noticeably smaller numerical range than the control limits suggested that the control limits could be too wide (permissive).
In the event of control limits that were too restrictive based on validation data, the original limit-setting dataset (from phase 1) was revisited, and inclusion/exclusion of extraneous values was reassessed. Recalculation of the mean, SD dup , CV, and control limits was performed as needed. scil Vet ABC data) were used for analysis, as the intent was to reflect stable instrument performance.
The following software settings and data were used as EZ Rules 3 input:
• Start-up mode • Instability "off"
• Using "manual selection", 1-3s with n = 1 and 1-3s with n = 2 were chosen for evaluation.
• "Decision level" was either the mean value (for RPT) or the manufacturer's target value (for commercial QCM). To obtain the RPT mean, measurand concentrations for each pair in the dataset were averaged. Next, the mean of all the averages was calculated.
• "Stable imprecision" was the CV value (for RPT, calculated for each measurand from the mean and SD dup ; for commercial QCM, calculated for each measurand from the mean and SD of the dataset)
• "Stable inaccuracy" was either zero (for RPT) or the absolute % bias calculated using the manufacturer's target value for commercial QCM, according to the formula:
• "Total error" starting values entered were draft values recommended by the ASVCP for hematology measurands. Power-function curves generated by the program for the chosen rule and conditions (referred to by the program as "critical error/ sigma-metrics graphs" or "power-function graphs") were reviewed to determine the possible Ped and Pfr given the specified conditions. 12 The program calculates a sigma metric for each set of conditions according to the formula:
TE a values were adjusted, as needed, to determine the smallest TE a possible while keeping the Ped ≥ 85% and the Pfr ≤ 5% for 1-3s with n = 1 and for 1-3s with n = 2.
| Challenging RPT control limits
In phase 4 of the study, carried out in the summer and fall of 2016, analytical error was deliberately created for a small number of specimens to challenge the control limits established in phases 1 and 2 of the study. Error was created using canine specimens selected as described for phase 1 of the study. Errors were created via specimen aging (second replicate much greater than 24 hours old) and analysis of the second replicate using an incorrect species setting or specimen dilution (aliquot for second replicate diluted This is the smallest TE a value that allowed a Ped ≥ 85% and a Pfr < 5% for 1-3s with n = 1, given the specified conditions (see text). f In this context, "n" refers to the number of control measurements per QC event. In practicality, RPT-QC is an n = 1 procedure if 1 patient specimen is chosen per day. 
| RESULTS
| Establishing RPT control limits
A total of n = 23 Advia differences and n = 22 ABC differences were available for RPT limit-setting. Tables 1 and 2 show the number of extraneous data points eliminated from each measurand's dataset and the final limits for each measurand. Figure 1 illustrates control limits before and after removal of outlying values. Figure 2 illustrates difference data having no obvious extraneous values.
| Validating RPT control limits
A total of n = 23 Advia differences and n = 23 ABC differences were available for RPT limit validation. Tables 3 and 4 summarize phase 2 data and final control limits. For 2 measurands (Advia HCT and ABC WBC), control limits were revised following examination of the phase 2 validation data. For the Advia 120 HCT data, an extraneous value was originally eliminated during phase 1 of the study, resulting in a control limit of 0 AE 3.04. Review of the phase 2 validation data showed that 5/23 differences were outside these limits. Inclusion of the outlying value originally omitted yielded limits of 0 AE 3.33; only 3 differences in the validation dataset were outside those limits. Accordingly, the latter limit was chosen for phase 3. Similarly, for the scil Vet ABC WBC data, consideration was given to eliminating 2 extraneous values from the limit-setting data used in phase 1, resulting in limits of 0 AE 1.16. Review of the phase 2 validation data showed that 5/23 differences were outside these limits. Elimination of only 1 extraneous value (rather than 2) from the phase 1 dataset yielded limits of 0 AE 1.52; only 2 differences in the validation dataset were outside those limits. Accordingly, the latter limit was chosen for phase 3. Tables 5 and 6 This is the smallest TE a value that allowed a Ped ≥ 85% and a Pfr < 5% for 1-3s with n = 1, given the specified conditions (see text). f In this context, "n" refers to the number of control measurements per QC event. In practicality, RPT-QC is an n = 1 procedure if 1 patient specimen is chosen per day.
| Comparison of RPT-QC and Commercial
QCM-QC
achievable TE a for 1-3s with n = 1, with Ped ≥ 85% and Pfr < 5%, was close to ASVCP draft TE a recommendation of 20%. Given the stated conditions, performance of RPT-PLT did not permit an achievable TE a < 34%. Similarly, for the scil Vet ABC, with the exception of RPT-WBC and RPT-PLT, achievable TE a for 1-3s with n = 1, with Ped ≥ 85% and Pfr < 5%, was also close to ASVCP draft TE a recommendations. Given the stated conditions, the performance of RPT-WBC did not permit an achievable TE a < 37%; performance of RPT-PLT did not permit an achievable TE a < 28%.
Given that only relatively high achievable TE a values were possible for the Advia RPT-PLT and the ABC RPT-WBC and PLT, the alternative rule 1-2.5s was investigated. With a 1-2.5s rule and an n = 1 (with Ped ≥ 85% and Pfr < 5%), slightly lower achievable TE a values were possible: 30% for Advia RPT-PLT, 34% for ABC RPT-WBC, and 25% for ABC RPT-PLT. Figure 3 shows a power-function graph for Advia 120 PLT-RPT data. Tables 7 and 8 summarize challenge data accumulated as part of this study. Dilution was the most reliable mechanism for inducing data error that was flagged by the chosen RPT control limits. Using an incorrect species setting, an expired reagent pack, or an aged sample caused detectable errors for some, but not all, measurands.
| Challenging RPT control limits
| DISCUSSION
Establishing control limits was the most challenging aspect of this work. The statistical principle underlying control limit-setting in statistical QC is that, in a stable test system subject only for occasional random errors, control data should follow a Gaussian distribution, ie, 95% of values should fall within AE 2SD of the mean.
14 In a dataset of 20 differences (as measured by a stable test system), this means that 1 difference should fall outside the control limits and 19 should fall within the limits. Although this guiding principle was used during control limit-setting, the decision of whether to omit extraneous values included a subjective element. For the datasets of n = 22 and n = 23 values used in this study, a maximum of 2 outlying values per measurand were eliminated during control limit-setting-this generally yielded limits that subjectively appeared appropriate. For 2 measurands (the Advia 120 HCT and scil Vet ABC WBC), limits originally determined during phase 1 were found to be too restrictive based on phase 2 validation data and were revised for purposes of Table S1 ).
Interestingly, RPT data for 1 measurand (the scil Vet ABC MCV, depicted in Figure 2) showed little variation, which reflects analytical The measure of error detection performance for RPT-QC and QCM-QC in this study was "achievable TE a ," which refers to the amount of analytical error for which the statistical QC procedure in question can provide control, given the specified conditions (ie, control rule, Ped, Pfr, CV, and %bias). In statistical QC, a quality specification is determined prior to QC validation (the procedure during which optimal control rule(s) are chosen based on their Ped and Pfr).
In contrast, in this study, the control rule was predetermined, and different TE a values were evaluated until the desired Ped and Pfr could be (theoretically) achieved by that rule given the measurand's CV and %bias for the control material used (patient specimen or commercial QCM). The "achievable TE a " was the numerically smallest TE a value resulting in a Ped ≥ 85% and a Pfr ≤ 5% for 1-3s and n = 1 or n = 2, based on evaluation of EZ Rules 3 power-function curves. The table in Appendix 1 summarizes achievable TE a for the 1-3s rule with n = 1 or n = 2, given specific CV values, and can be used to estimate achievable TE a if CV is known.
ASVCP TE a recommendations are a recommended starting point;
however, these recommendations may not be achievable for all measurands and instruments, depending on analytical performance Overall, RPT-QC and QC using commercial QCM had similar theoretical performance for analytical error detection based on analysis using EZ Rules 3 software and inspection of resulting power-function curves. The focus was on determining achievable TE a for the 1-3s rule,
given the observed CV and %Bias for each measurand and a goal of having ≥85% Ped and <5% Pfr with n = 1 measurement per QC event.
RPT as performed during this study (ie, where 1 fresh patient specimen is chosen per day), is inherently an n = 1 QC procedure; however, analysis of the same specimen twice (or analysis of 2 independent specimens) could be used to achieve 2 data points per QC event (ie, n = 2). That error detection performance with n = 2 measurements per QC event was greater than that with n = 1 measurement per QC event is not surprising. The 1-3s rule was chosen because this rule has a very low false rejection rate (ie, high specificity for "diagnosing" analytical error). In a stable test system subject to only occasional random errors and for which control data follow a Gaussian distribution, there is only a 0.3% chance that a given control data point will fall farther than 3SD from the mean. In those instances, there is usually a true problem with the test system. 14 A further consideration in choosing 1-3s as a single control rule was that this rule should be relatively easy for nonlaboratorians (eg, practitioners using in-clinic hematology instruments) to calculate and implement.
In reference laboratories, the goal for Ped is more commonly ≥90%. The rationale for choosing a more modest goal of Ped ≥ 85% for this study was that having at least an 85% sensitivity for "diagnosing" analytical error is reasonable for a QC procedure that could be T A B L E 6 Theoretical performance of commercial quality control material (QCM) with a 1-3s control rule-scil Vet ABC is variable. 15 Additionally, a goal of Ped ≥ 90% is not achievable with n = 1, whereas Ped ≥ 85% is achievable with a single control.
A question is whether RPT control limits based on 0 AE 3SD (vs, eg, mean difference AE 3SD) are appropriate for measurands where storage artifact introduces change in a particular "direction" away from zero. This limitation of unidirectional change for some measurands is not directly addressed by Westgard. 4 In traditional statistical QC using commercial QCM, control limits are spread around the data mean because one is repeatedly measuring the same, stable control material over time. In RPT-QC, a new, independent patient specimen is used for each QC event. The hypothesis is that there will be no difference between the original and repeat result for each specimen-intuitively, it makes sense for control limits to be spread around the value zero. Of the measurands evaluated in our study, MCV and HCT are most likely to skew to one side of zero (because both MCV and HCT are expected to increase with storage, resulting in all negative differences if day 2 results are subtracted from day 1 results). Although MCV and HCT differences will skew toward 1 control limit, from our analysis, this does not appear to limit utility of the limits for routine QC (based on achievable TE a ). If the instrument operator knows that MCV and HCT differences should be predominantly negative, then the presence of positive differences (particularly for MCV) can raise concern for test system malfunction.
Additionally, assessment of test system malfunction should be based on evaluation of all measurands, not just one. Finally, assessment of possible test system malfunction should not be made unless any difference (negative or positive) exceeds 3SD (thus likely exceeds the error specification, suggesting there is error that can interfere with patient results interpretation).
Given the stated conditions, both RPT-QC and QCM-QC were able to achieve TE a values similar to draft recommendations for hema- Pfr, Ped, n, and R. Pfr = probability of false rejection, expressed as a decimal percentage. Ped = probability of error detection, expressed as a decimal percentage. N = number of control data points (eg, n = 2 could be 2 control materials measured singly or 1 material measured twice). R = number of analytical runs. In this example, given the stated CV and bias for this measurand (see Table 1 ) and a TEa of 30%, the 1-3s rule has only 73% Ped with n = 1; however, the 1-2.5s rule has 86% Ped with n = 1. Note that the 1-2.5s rule with n = 1 has 1% Pfr, whereas the 1-3s rule has 0% Pfr T A B L E The first replicate was measured using the "canine" setting; the second replicate was measured using the "equine" setting. The first replicate was measured using the fresh specimen (day of accession); the second replicate was measured after the specimen was aged in the refrigerator for 7 days. The specimen was rewarmed and thoroughly mixed prior to analysis.
That scil Vet ABC WBC-RPT had a high achievable TE a is more surprising. This is due to the relatively high imprecision (since bias was set at zero for purposes of EZ Rules 3 analysis). Review of the raw data did not show any flags indicating a problem with WBC enumeration.
By comparison, the CV based on commercial level 2 QCM for this measurand (given in This is in contrast to MCV, where a lack of detectable variability may prevent the use of RPT-QC. As for MCV, demonstration of actual RPT-QC performance for WBC using this instrument is needed.
Challenge data for this study are limited but illustrate that deliberate "errors" (ie, large differences) induced by specimen manipulation can be detected by the chosen control limits. Unsurprisingly, dilution (the most egregious specimen manipulation) created the largest "error" for both instruments. The fact that MCV differences were not affected by dilution is not unexpected, given that the diluted aliquot was measured immediately following dilution. It seems likely that not enough time elapsed to permit significant RBC changes caused by the altered osmolar environment, or that any changes were simply not marked enough to shift this mean value.
Prolonged specimen storage induced detectable "error" for HGB, HCT, and MCV for both instruments. This too is not unexpected.
Based on the Furlanello study, each of these measurands changed significantly from baseline in canine EDTA whole blood specimens after 12 hours of storage at both 4 and 24°C. 2 RBC lysis and swelling are expected to worsen with increasing storage and would predominantly affect these measurands, particularly following a week of storage. Performing repeat measurements using an incorrect species setting caused the least amount of "error" for both instruments. ; however, this aspect of RPT-QC remains to be investigated in veterinary laboratory medicine.
| CONCLUSION S
This study may be considered a "proof-of-concept" study showing that QC using repeat testing of patient specimens under prescribed conditions with customized control limits should perform similarly to QC using commercial QCM. Both are versions of statistical QC.
Potential advantages of RPT-QC are species-specific matrix, lowcost, and absence of deterioration of the QC material over time (as long as a fresh specimen is used each day and specimen handling occurs under uniform conditions). A potential disadvantage is daily access to healthy patient specimens. A related disadvantage is the ability to carry out RPT-QC on a day after a clinic or laboratory has been closed for several days without patient specimens being measured (eg, Mondays, or following a holiday). Whether hematology RPT-QC could be performed using 2-day-old specimens (eg, original measurement on Saturday, repeat measurement on Monday) was not investigated. From this study, RPT-QC appears to be a viable QC option for sites performing hematology testing. A challenge is setting RPT control limits, and consultation with a QC expert may be needed. Given that this study investigated theoretical performance, further investigation is needed to confirm the actual analytical error detection performance of RPT-QC vs QCM-QC over time, and further investigation is also needed to determine whether RPT-QC using patient specimens having abnormal measurand concentrations The first replicate was measured using the "canine" setting; the second replicate was measured using the "equine" setting.
b
The first replicate was measured using the fresh specimen (day of accession); the second replicate was measured after the specimen was aged in the refrigerator for the specified number of days. The specimen aliquot used for repeat measurement was diluted using 0.9% sodium chloride and measured immediately following dilution. T A B L E A 1 Achievable allowable total error (TE a ) in repeat patient testing quality control (RPT-QC). Achievable TE a for the 1-3s control rule given the following conditions: Probability of error detection (Ped) ≥ 85%, probability of false rejection (Pfr) ≤ 5%, n = 1 or n = 2 measurements per QC event, bias = 0%, and varying CV To use this table, choose n = 1 or n = 2. Remember that n = 2 can be 1 specimen measured twice or 2 independent specimens. In the appropriate column, choose the CV value closest to the observed CV for your instrument and measurand. The corresponding TE a value on the left indicates the minimum achievable TE a under those circumstances. If the observed CV is higher than the highest CV shown in this table (ie, >15%), then achievable TE a will be >75% and acceptable error control using RPT-QC will be unlikely. 
